Bidisomide (SC40230)
(Synonyms: 比地索胺; SC40230) 目录号 : GC34050Bidisomide (SC40230) (SC40230) 是一种 I 类抗心律失常药物。
Cas No.:116078-65-0
Sample solution is provided at 25 µL, 10mM.
Bidisomide (SC40230) is a class I antiarrhythmic agent.
The antiarrhythmic effects of Bidisomide, a new class I antiarrhythmic drug is investigated in early-phase ventricular arrhythmias induced by coronary artery occlusion and reperfusion in anesthetized rats. Bidisomide (5 mg/kg) reduces the number of premature ventricular complexes and the incidence of ventricular tachycardia and ventricular fibrillation similarly to Mexiletine (MXT) and Disopyramide (DSP) in rats with ventricular arrhythmias induced by coronary artery occlusion. In rats with ventricular arrhythmias induced by coronary artery reperfusion following a 5 min coronary occlusion, the antiarrhythmic effects of 5 mg/kg of Bidisomide are similar to those of the same doses of MXT and DSP. All three drugs significantly slow the heart rate[1].
[1]. Komori S, et al. Effects of bidisomide (SC-40230), a new class I antiarrhythmic agent, on ventricular arrhythmias induced by coronary artery occlusion and reperfusion in anesthetized rats; comparison with mexiletine and disopyramide. Heart Vessels. 1995;10(1):7-11.
Animal experiment: | Rats[1]Male Sprague-Dawley rats weighing 200-280g are used. Thirty-nine rats receive intravenous infusion of saline (n=9), Bidisomide (5 mg/kg, n=10), Mexiletine (MXT, 5 mg/kg, n=10), or Disopyramide (DSP, 5 mg/kg, n=10). In preliminary experiments, 5 mg/kg of MXT and DSP have significant antiarrhythmic effects. The same dose of Bidisomide is used. The injection volume of each agent is adjusted to 0.5 mL with saline. Coronary artery occlusion is induced 5min after drug administration. Electrocardiograms and systemic arterial blood pressure are recorded for 30 min after induction of coronary artery occlusion. |
References: [1]. Komori S, et al. Effects of bidisomide (SC-40230), a new class I antiarrhythmic agent, on ventricular arrhythmias induced by coronary artery occlusion and reperfusion in anesthetized rats; comparison with mexiletine and disopyramide. Heart Vessels. 1995;10(1):7-11. |
Cas No. | 116078-65-0 | SDF | |
别名 | 比地索胺; SC40230 | ||
Canonical SMILES | CC(C)N(C(C)=O)CCC(C(N)=O)(C1=C(C=CC=C1)Cl)CCN2CCCCC2 | ||
分子式 | C22H34ClN3O2 | 分子量 | 407.98 |
溶解度 | Soluble in DMSO | 储存条件 | Store at -20°C |
General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。 储备液的保存方式和期限:-80°C 储存时,请在 6 个月内使用,-20°C 储存时,请在 1 个月内使用。 为了提高溶解度,请将管子加热至37℃,然后在超声波浴中震荡一段时间。 |
||
Shipping Condition | 评估样品解决方案:配备蓝冰进行发货。所有其他可用尺寸:配备RT,或根据请求配备蓝冰。 |
制备储备液 | |||
1 mg | 5 mg | 10 mg | |
1 mM | 2.4511 mL | 12.2555 mL | 24.511 mL |
5 mM | 0.4902 mL | 2.4511 mL | 4.9022 mL |
10 mM | 0.2451 mL | 1.2256 mL | 2.4511 mL |
第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量) | ||||||||||
给药剂量 | mg/kg | 动物平均体重 | g | 每只动物给药体积 | ul | 动物数量 | 只 | |||
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系GLPBIO为您提供正确的澄清溶液配方) | ||||||||||
% DMSO % % Tween 80 % saline | ||||||||||
计算重置 |
计算结果:
工作液浓度: mg/ml;
DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,
体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL saline,混匀澄清。
1. 首先保证母液是澄清的;
2.
一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。
Quality Control & SDS
- View current batch:
- Purity: >99.50%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet